Literature DB >> 20190276

Identification and characterization of novel parathyroid-specific transcription factor Glial Cells Missing Homolog B (GCMB) mutations in eight families with autosomal recessive hypoparathyroidism.

Michael R Bowl1, Samantha M Mirczuk, Irina V Grigorieva, Sian E Piret, Treena Cranston, Lorraine Southam, Jeremy Allgrove, Shailini Bahl, Caroline Brain, John Loughlin, Zulf Mughal, Fiona Ryan, Nick Shaw, Yogini V Thakker, Dov Tiosano, M Andrew Nesbit, Rajesh V Thakker.   

Abstract

GCMB is a member of the small transcription factor family GCM (glial cells missing), which are important regulators of development, present in vertebrates and some invertebrates. In man, GCMB encodes a 506 amino acid parathyroid gland-specific protein, mutations of which have been reported to cause both autosomal dominant and autosomal recessive hypoparathyroidism. We ascertained 18 affected individuals from 12 families with autosomal recessive hypoparathyroidism and have investigated them for GCMB abnormalities. Four different homozygous germline mutations were identified in eight families that originate from the Indian Subcontinent. These consisted of a novel nonsense mutation R39X; a missense mutation, R47L in two families; a novel missense mutation, R110W; and a novel frameshifting deletion, I298fsX307 in four families. Haplotype analysis, using polymorphic microsatellites from chromosome 6p23-24, revealed that R47L and I298fsX307 mutations arose either as ancient founders, or recurrent de novo mutations. Functional studies including: subcellular localization studies, EMSAs and luciferase-reporter assays, were undertaken and these demonstrated that: the R39X mutant failed to localize to the nucleus; the R47L and R110W mutants both lost DNA-binding ability; and the I298fsX307 mutant had reduced transactivational ability. In order to gain further insights, we undertook 3D-modeling of the GCMB DNA-binding domain, which revealed that the R110 residue is likely important for the structural integrity of helix 2, which forms part of the GCMB/DNA binding interface. Thus, our results, which expand the spectrum of hypoparathyroidism-associated GCMB mutations, help elucidate the molecular mechanisms underlying DNA-binding and transactivation that are required for this parathyroid-specific transcription factor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190276     DOI: 10.1093/hmg/ddq084

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  15 in total

Review 1.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 2.  Genetic Disorders of Parathyroid Development and Function.

Authors:  Rebecca J Gordon; Michael A Levine
Journal:  Endocrinol Metab Clin North Am       Date:  2018-10-12       Impact factor: 4.741

3.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

4.  Identification and characterization of C106R, a novel mutation in the DNA-binding domain of GCMB, in a family with autosomal-dominant hypoparathyroidism.

Authors:  Hyon-Seung Yi; Young Sil Eom; Ie Byung Park; Sangho Lee; Suntaek Hong; Harald Jüppner; Michael Mannstadt; Sihoon Lee
Journal:  Clin Endocrinol (Oxf)       Date:  2012-05       Impact factor: 3.478

5.  Mutational analysis of GCMB, a parathyroid-specific transcription factor, in parathyroid adenoma of primary hyperparathyroidism.

Authors:  Michael Mannstadt; Emily Holick; Wenping Zhao; Harald Jüppner
Journal:  J Endocrinol       Date:  2011-06-03       Impact factor: 4.286

6.  Specifying the molecular pattern of sporadic parathyroid tumorigenesis-The Y282D variant of the GCM2 gene.

Authors:  Elena Marchiori; Maria Rosa Pelizzo; Monika Herten; Danyelle M Townsend; Domenico Rubello; Isabella Merante Boschin
Journal:  Biomed Pharmacother       Date:  2017-06-09       Impact factor: 6.529

7.  A novel mutation in the GCM2 gene causing severe congenital isolated hypoparathyroidism.

Authors:  Daniel Doyle; Susan M Kirwin; Katia Sol-Church; Michael A Levine
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

Review 8.  Hormonal regulation of biomineralization.

Authors:  Andrew Arnold; Elaine Dennison; Christopher S Kovacs; Michael Mannstadt; René Rizzoli; Maria Luisa Brandi; Bart Clarke; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2021-03-16       Impact factor: 43.330

9.  Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism.

Authors:  Colin Patrick Hawkes; Dorothy I Shulman; Michael A Levine
Journal:  Eur J Endocrinol       Date:  2020-12       Impact factor: 6.664

10.  Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.

Authors:  Christopher J Ricketts; Mark R Morris; Dean Gentle; Salwati Shuib; Michael Brown; Noel Clarke; Wenbin Wei; Paul Nathan; Farida Latif; Eamonn R Maher
Journal:  Clin Epigenetics       Date:  2013-09-13       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.